New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2013
19:26 EDTJNJJ&J's Cordis announces two-year results from STROLL trial
Cordis, a unit of Johnson & Johnson, announced the presentation of the two-year STROLL study results. In the study, the average lesion length was 77 mm, 23.6% of patients presented with total occlusions and 47% of patients were diabetic. Freedom from clinically driven target lesion revascularization at two years was 80.3%. The 24-month primary patency rate for the S.M.A.R.T. Stent was 74.9% by Kaplan Meier estimate. The primary duplex patency rate was 83.5%. There were no major adverse events at 30 days after the initial index procedure, Cordis added. There was also a low rate of stent fractures noted at 12 months with no additional fractures reported out to 24 months, the company said. All stent fractures were Type I, least severe, and there were no incidents of more severe stent fractures. STROLL is a multicenter, non-randomized, single-arm, prospective trial comparing the safety and efficacy of the S.M.A.R.T. Stent with a previously published objective performance goal.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
19:49 EDTJNJJohnson & Johnson to open shared services headquarters in Florida
Subscribe for More Information
August 25, 2015
13:01 EDTJNJJ&J unit to sell Splenda brand to Heartland Food, terms not disclosed
Subscribe for More Information
09:03 EDTJNJAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
06:18 EDTJNJSears names Lynn Pendergrass as Hardlines president
Subscribe for More Information
August 21, 2015
09:01 EDTJNJLeerink medical devices analyst holds an analyst/industry conference call
Medical Device Analyst Newitter, along with MEDACorp Specialists Dorance Dillon and Terence Farrell, discuss the Centers for Medicare & Medicaid Services' recently proposed "Comprehensive Care For Joint Replacement Payment Model" and how this model might influence ortho pricing and hospital-vendor relationships on an Analyst/Industry conference call to be held on August 24 at 1 pm.
August 20, 2015
11:33 EDTJNJLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use